Myasthenia gravis (MG) is a chronic autoimmune disease causing muscle weakness that fluctuates throughout the day. Symptoms include drooping eyelids, difficulty speaking or swallowing, and limb fatigue. Because these symptoms change rapidly, doctors use standardized tools to track disease progression and treatment effectiveness. One of the most common methods is the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale.
Why the MG-ADL Scale Matters
Traditional neurological exams assess muscle strength, but don’t always reflect how symptoms disrupt daily life. The MG-ADL scale fills this gap by capturing patient-reported outcomes, meaning the score comes directly from the person living with MG, not just a doctor’s observation. This is crucial because MG impacts quality of life in ways that strength tests alone can’t measure.
Understanding the Scale’s Components
The MG-ADL scale evaluates symptoms across eight functional domains. These include:
- Bulbar Symptoms : Weakness affecting speech, chewing, and swallowing.
- Respiratory Symptoms : Muscle weakness impairing breathing.
- Ocular Symptoms : Double vision and drooping eyelids.
- Limb Symptoms : Weakness in arms and legs.
Each category assesses how symptoms interfere with basic activities. For example, the scale considers whether weakness makes brushing hair difficult or standing from a chair exhausting.
How Scoring Works
The MG-ADL questionnaire assigns a severity score (0-3) to each of the eight items:
- 0 : No symptoms
- 1 : Mild symptoms
- 2 : Moderate symptoms
- 3 : Severe symptoms
Total scores range from 0 to 24, with higher numbers indicating a greater symptom burden. The scale doesn’t require testing at a specific time of day, but instead captures overall symptom experience over several days. It’s important that patients only report symptoms directly caused by MG, not unrelated conditions.
Using the Scale in Practice
Neurologists use the MG-ADL to establish a baseline at diagnosis or when starting new treatments. Tracking changes over time is more valuable than a single score. Studies suggest patient-reported scores can reveal issues missed during brief physical exams. A two-point improvement is often considered clinically significant in research, but doctors emphasize that individual improvements matter more than arbitrary benchmarks.
The Role of Patient Tracking
The MG-ADL isn’t just for clinic visits. Patients can self-administer the scale to monitor symptom fluctuations, especially when starting new therapies. Regular tracking helps identify patterns. For example, some treatments work in cycles, with symptom relief followed by gradual return. Recording scores periodically reveals these trends.
Communicating With Your Doctor
The MG-ADL can spark productive conversations with healthcare teams. Sharing symptom patterns or scores helps doctors understand how MG affects daily functioning. Discussing challenges with treatment adherence (side effects, scheduling) is also important. Ultimately, the goal isn’t just a number on a scale, but whether a patient’s quality of life is improving.
The MG-ADL scale is a tool for understanding how MG affects daily life. While not perfect, it provides valuable insight for both patients and doctors, helping optimize treatment and improve overall well-being.
